Data sifted from the subset of an otherwise-failed Phase IIb trial helped Anthera Pharmaceuticals Inc. persuade the FDA to bless the planned Phase III lupus program envisioned with blisibimod, a peptibody that targets high levels of B-cell activating factor (BAFF). Read More
Targacept Inc.'s TC-5619 missed its endpoint in a Phase II study in inattentive-predominant attention deficit hyperactivity disorder (iADHD), the latest in a string of disappointing news for its neuronal nicotinic receptor (NNR) pipeline. Read More
Threshold Pharmaceuticals Inc. saw its shares fall 19.7 percent Monday, following release of an update to its Phase IIb trial of TH-302 in pancreatic cancer. Read More
LONDON – Vasopharm GmbH announced that the Phase IIa trial of its nitric oxide inhibitor VAS203 not only cleared all the safety, tolerability and pharmacokinetic hurdles, but also led to "substantially improved" neurological recovery at six months in traumatic brain injury (TBI) patients. Read More
• Bionomics Ltd., of Adelaide, Australia, has acquired the private biotechnology company Eclipse Therapeutics Inc., of San Diego, in a $10 million deal. Read More
• Jennerex Inc., of San Francisco, presented Phase II data on JX-594, its engineered oncolytic immunotherapy, delivered first intravenously and then through intra-tumoral route, demonstrating safety, disease control and tumor response in hepatocellular carcinoma (HCC). Read More
• Life Technologies Corp., of Carlsbad, Calif., entered a master development agreement with Bristol-Myers Squibb Co., of New York, for current and future companion diagnostics projects. Read More
• Diffusion Pharmaceuticals LLC, of Charlottesville, Va., closed a $5 million private financing consisting of convertible notes issued primarily to existing investors. Read More
